PureTech Health (LON:PRTC) Shares Cross Below Fifty Day Moving Average – Time to Sell?

PureTech Health plc (LON:PRTC)’s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 129.20 and traded as low as GBX 124.53. PureTech Health shares last traded at GBX 125.61, with a volume of 358,950 shares trading hands.

Analysts Set New Price Targets

Separately, Peel Hunt reiterated a “buy” rating and set a GBX 508 price objective on shares of PureTech Health in a research report on Monday, July 13th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of GBX 508.

PureTech Health Stock Performance

The company has a debt-to-equity ratio of 6.33, a quick ratio of 2.51 and a current ratio of 6.59. The company has a 50 day moving average price of GBX 129.20 and a 200 day moving average price of GBX 126.96. The company has a market capitalization of £305.25 million, a price-to-earnings ratio of -2.73 and a beta of 0.79.

Insider Transactions at PureTech Health

In other news, insider John LaMattina acquired 50,000 shares of PureTech Health stock in a transaction on Wednesday, July 8th. The stock was purchased at an average price of GBX 119 per share, with a total value of £59,500. Also, insider Michele Holcomb acquired 31,481 shares of the firm’s stock in a transaction dated Wednesday, July 8th. The shares were purchased at an average price of GBX 119 per share, with a total value of £37,462.39. Over the last ninety days, insiders bought 147,849 shares of company stock worth $17,594,031. 13.35% of the stock is currently owned by insiders.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.